A simple, rapid, precise and accurate HPTLC method was developed and validated for the estimation of Nintedanib, a novel tyrosine kinase inhibitor used in idiopathic pulmonary fibrosis, in bulk drug. Chromatography was carried out using silica gel 60 F254 TLC plate and mobile phase Chloroform: Methanol in the ratio 7:3 v/v. The densitometric determination was done at 386 nm. Regression analysis data for the calibration plot were indicative of a good linear relationship between response and concentration over the range of 800-3200 ng/band. The variance (r) was found to be 0.999. The LOD & LOQ were found to be 83.357 ng/band & 252.599 ng/band respectively. The method was validated according to ICH Q2R1 guideline. The method was precise and accurate with %RSD 0.5323 (intraday) and 0.6939 (interday) respectively and percentage recoveries in the range 99.6459 % – 101.4298 %.
We are working on a new version of the website! To complete the upgrade, Sciforum will be unavailable on Saturday 18 July from 09:00 to 15:00 CEST. Thank you for your understanding.
Previous Article in event
Previous Article in session
Next Article in event
Next Article in session
VALIDATED HPTLC METHOD FOR THE DETERMINATION OF NINTEDANIB IN BULK DRUG
Published:
14 November 2018
by MDPI
in The 22nd International Electronic Conference on Synthetic Organic Chemistry
session Bioorganic, Medicinal and Natural Products Chemistry
Abstract:
Keywords: Nintedanib; HPTLC; ICH Q2R1; idiopathic pulmonary fibrosis
